Abpro specializes in monoclonal antibody development for research, diagnostics, and therapeutic purposes.

Abpro specializes in monoclonal antibody development for research, diagnostics, and therapeutic purposes. Our proprietary HTP™ platform generates premium antibodies in just 2-3 months. The HTP™ platform routinely finds success in producing antibodies to difficult targets such as GPCRs, conformation specific, cell surface receptors, phospho-specific, 1-amino acid specificity, anti-idiotypes, and high homology.